Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes
- PMID: 8113385
- PMCID: PMC293858
- DOI: 10.1172/JCI116994
Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes
Abstract
Plasmodium falciparum infecting hemoglobin (Hb)H and/or Hb Constant Spring erythrocytes has higher resistance to artemisinin in vitro than when infecting normal erythrocytes. This is due to low drug accumulation of infected erythrocytes resulting from competition with uninfected variant erythrocytes, which have a higher accumulation capacity than genetically normal cells. Drug accumulation of the parasite was shown to be saturable and dependent on metabolic energy. The 50% inhibitory concentrations (IC50's) for the parasite in HbH/Hb Constant Spring erythrocytes were decreased when normal erythrocytes were added to the infected cells, and correspondingly, the IC50's in normal erythrocytes were increased when HbH/Hb Constant Spring erythrocytes were added to the infected cells. The changes of IC50 corresponded to the variation in drug accumulation of mixtures of normal and variant erythrocytes of different compositions. The IC50's for the parasite in variant erythrocytes were also greatly decreased when the hematocrit of the culture was lowered, while the IC50's in normal erythrocytes were independent of the hematocrit. The increase in IC50 values for the parasites infecting variant erythrocytes was also related to the decrease in parasite accumulation, indicating that drug accumulation capacity of the parasite also has a role in determining drug sensitivity. Artemisinin sensitivity therefore is determined by its accessibility to the parasite, which is decreased in infected variant erythrocytes.
Similar articles
-
Decreased sensitivity of artesunate and chloroquine of Plasmodium falciparum infecting hemoglobin H and/or hemoglobin constant spring erythrocytes.J Clin Invest. 1989 Feb;83(2):502-5. doi: 10.1172/JCI113910. J Clin Invest. 1989. PMID: 2643631 Free PMC article.
-
Binding of dihydroartemisinin to hemoglobin H: role in drug accumulation and host-induced antimalarial ineffectiveness of alpha-thalassemic erythrocytes.Mol Pharmacol. 1998 Mar;53(3):492-6. doi: 10.1124/mol.53.3.492. Mol Pharmacol. 1998. PMID: 9495816
-
Inactivation of artemisinin by thalassemic erythrocytes.Biochem Pharmacol. 2000 Jun 1;59(11):1337-44. doi: 10.1016/s0006-2952(00)00271-9. Biochem Pharmacol. 2000. PMID: 10751542
-
Increased susceptibility of malaria-infected variant erythrocytes to the mononuclear phagocyte system.Blood Cells. 1990;16(2-3):591-7. Blood Cells. 1990. PMID: 2098019 Review.
-
Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria.Annu Rev Microbiol. 2020 Sep 8;74:431-454. doi: 10.1146/annurev-micro-020518-115546. Annu Rev Microbiol. 2020. PMID: 32905757 Free PMC article. Review.
Cited by
-
Artemisone uptake in Plasmodium falciparum-infected erythrocytes.Antimicrob Agents Chemother. 2011 Feb;55(2):550-6. doi: 10.1128/AAC.01216-10. Epub 2010 Dec 6. Antimicrob Agents Chemother. 2011. PMID: 21135191 Free PMC article.
-
Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.Clin Infect Dis. 2018 Feb 10;66(5):799-804. doi: 10.1093/cid/cix785. Clin Infect Dis. 2018. PMID: 29370347 Free PMC article.
-
Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand.Malar J. 2011 Dec 15;10:368. doi: 10.1186/1475-2875-10-368. Malar J. 2011. PMID: 22171972 Free PMC article.
-
Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali.Malar J. 2010 Nov 21;9:332. doi: 10.1186/1475-2875-9-332. Malar J. 2010. PMID: 21092137 Free PMC article. Clinical Trial.
-
Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.Pediatr Res. 2009 May;65(5 Pt 2):64R-70R. doi: 10.1203/PDR.0b013e3181a0977e. Pediatr Res. 2009. PMID: 19918214 Free PMC article. Review.